GRAIL, Inc. Common Stock — Rendiconto Finanziario Trimestrale (NASDAQ:GRAL)

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 2.1363 B
Employee 910
Founded 2015
CEO N/A
Website www.grail.com
Headquarter Delaware, United States
FIGI BBG01N6CGW43
Industry Diagnostica e Ricerca

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

2.14 B Capitalizzazione di mercato

Rapporto prezzo/utili

-7.7

Rapporto prezzo/fatturato

21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.